Glactone Pharma develops novel drugs that target STAT3, a key transcription factor signaling pathway, for the treatment of advanced and drug resistant cancers to improve the lives of cancer patients.

Glactone Pharma AB

Our vision

We strive to build strong science and robust data to deliver real and meaningful benefits to patients. Learn more about our projects.

Our mission

We develop unique small-molecule inhibitors of STAT3 (Signal Transducer and Activator of Transcription 3) to enhance the efficacy and response of immunotherapies in immuno-oncology and for the treatment of advanced drug resistant cancers.

News & press releases

Archive >

Glactone Pharma receives funding from Swelife and Medtech4health

2018-05-24

In strong competition and after external examination, Glactone Pharma in collaboration with researchers from Karolinska Institutet and Lund... [Read more]

Glactone Pharma erhåller finansiering från Swelife och Medtech4health

2018-05-24

I stark konkurrens och efter extern granskning har Glactone Pharma i samarbete med forskare från Karolinska Institutet och... [Read more]